marijuana stocks

Namaste Announces the Pre-Launch of CannMart.com in Anticipation of Receiving Canada’s First Medical Cannabis Sales-Only License

Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV:N.V) (M5BQ.F) (NXTTF) is pleased to announce that the Company has pre-launched its revolutionary medical cannabis online marketplace through its wholly-owned subsidiary, CannMart Inc. (“CannMart” or “CannMart.com”). CannMart is poised to be Canada’s first medical cannabis “sales-only” license under Health Canada’s Access to Cannabis for Medical Purposes (“ACMPR”) program. The Company has pre-launched CannMart’s website, CannMart.com, which will allow the Company to commence sales immediately after receiving its license. Receipt of its sales license, coupled with the official launch of CannMart.com, will represent the most significant achievement in the Company’s history and will be the catalyst for Namaste introducing legal cannabis sales into its global e-commerce platform.

Namaste is pleased to report that it received communication from Health Canada on September 6 th, 2018, and the Company would like to reaffirm that the application is progressing. CannMart’s license, which is the first of its kind in Canada , will enable Namaste to procure and sell medical cannabis from both domestic and international Health Canada approved cultivators, which will be offered in an AI-driven e-commerce marketplace designed to provide a unique and personalized experience for each patient. Namaste has secured supply and holds inventory of a carefully curated selection of high-quality medical cannabis flower and oil.

Namaste has successfully launched and operates the largest global e-commerce marketplace which retails cannabis ancillary devices on 30 websites in 20 countries. The Company maintains a database of over 1.5 million customers and has developed and acquired leading e-commerce technology platforms including Findify.io (“Findify”), a leading e-commerce AI company, and NamasteMD (“NamasteMD.com”), Canada’s first fully integrated patient consultation portal available in the Apple and Google Play stores and online. Namaste’s technology team have incorporated cutting-edge e-commerce AI which will offer a personalized user experience for every patient ordering through CannMart.com. The Company anticipates that the launch of CannMart’s website and receipt of its sales license will solidify Namaste’s position as the leader in cannabis e-commerce.

By receiving its sales license, Namaste will complete the vision that it set out to achieve only two short years ago. What the Company has been able to achieve has been truly remarkable as many of its initiatives have been revolutionary to the cannabis space. In a very short period of time, both the NamasteMD App and recently released My Uppy Cannabis Journal App have demonstrated that the Company’s forward-thinking strategies are highly successful. With over 18,000 registered users on NamasteMD, over 18,000 downloads of My Uppy, and Namaste’s Canadian database of over 17,000 vaporizer customers (derived through NamasteVapes.ca and Everyonedoesit.ca), together totaling a user-base of over 52,000 people, the Company, upon receipt of its sales license will be well positioned to leverage its database, technology and e-commerce expertise to disrupt online cannabis sales in Canada and then globally.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

The Alkaline Water Company Inc. (WTER) (WTER.V) Reports Record Monthly Sales of $3.8 Million

The Alkaline Water Company Reports Record Monthly Sales of $3.8 Million The…

Organigram Holdings Inc. (OGI) to Report First Quarter Fiscal 2023 Results on January 12, 2023

Organigram to Report First Quarter Fiscal 2023 Results on January 12, 2023…

Insys Therapeutics, Inc. (INSY) Will SYNDROS Potential Replace SUBSYS Challenges

Will SYNDROS Potential Replace SUBSYS Challenges Traders News Source, a leading independent…

GT Biopharma Inc. (GTBP) Begins Manufacturing of “Non-Opioid” Pain-Brake Drug

GT Biopharma Begins Manufacturing of “Non-Opioid” Pain-Brake Drug to Compete in Multi-Billion…